Recurrent Bacillus subtilis Var. Natto Bacteremia and Review of the Literature on Bacillus subtilis: The First Case Report

09 February 2024 : Case report Japan

Challenging differential diagnosis, Unusual or unexpected effect of treatment, Diagnostic / therapeutic accidents, Rare disease

Kazuhiro Ishikawa

^1ABCDEF, Ryo Hasegawa^2ABCDEF, Keitaro Furukawa^3C, Fujimi Kawai^4AF, Yuki Uehara^5ABCDEF, Kiyofumi Ohkusu^3CD, Nobuyoshi Mori^1ABCDEF*

DOI: 10.12659/AJCR.942553

Am J Case Rep 2024; 25:e942553

Background Case Report Discussion Conclusions References:

Related articles Order reprints Share article Share by email

View HTML version

Table 1. Susceptibility panel.

	MIC	Susceptibility		MIC	Susceptibility
PCG	≤0.06	S	EM	≤0.5	S
CEZ	≤8	S	CLDM	≤0.5	S
CTRX	≤8	S	MINO	≤4	S
IMP/CS	≤0.5	S	LVFX	≤1	S
GM	≤4	S
^* Interpretation (susceptible, intermediate, or resistant) was based on the Clinical and Laboratory Standards Institute (CLSI) criteria (M45). For other antimicrobials, the breakpoints for spp. in the CLSI guidelines M 100-S22 and S24 were used according to the previous study []. PCG – penicillin G; CEZ – cefazoline; CTRX – ceftriaxone; IPM/CS – imipenem/cilastatin; EM – erythromycin; GM – gentamycin; CLDN – clindamycin; MINO – minocycline; LVFX – levofloxacin; MIC – minimum inhibitory concentration; S – susceptible.

Back to the Article